AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.The Motley Fool • 06/12/26
AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year ResultsPRNewsWire • 06/12/26
Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $22524/7 Wall Street • 06/11/26
Will Skyrizi & Rinvoq Continue to Drive AbbVie's Topline Through 2026?Zacks Investment Research • 06/11/26
FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter MeansGlobeNewsWire • 06/10/26
AbbVie Inc. (ABBV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/09/26
Middle East Erupts Again: Buy these Healthcare ETFs Before the Next StrikeZacks Investment Research • 06/09/26
Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month?Zacks Investment Research • 06/08/26
AbbVie, UnitedHealth, Sabra Health Care And A Consumer Defensive Stock On CNBC's 'Final Trades'Benzinga • 06/08/26
AbbVie Inc. (ABBV) Presents at EU Clinical Trial Regulation: Latest Developments and Upcoming Opportunities TranscriptSeeking Alpha • 05/29/26